Sei Investments Co. Increases Stock Position in Insmed Incorporated (NASDAQ:INSM)

Sei Investments Co. raised its holdings in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 8.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 362,616 shares of the biopharmaceutical company's stock after purchasing an additional 29,019 shares during the quarter. Sei Investments Co. owned approximately 0.20% of Insmed worth $25,035,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Jennison Associates LLC lifted its stake in shares of Insmed by 0.6% during the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company's stock worth $53,424,000 after buying an additional 4,560 shares during the last quarter. Capital CS Group LLC bought a new position in Insmed in the 4th quarter valued at about $586,000. Orion Portfolio Solutions LLC lifted its position in Insmed by 48.5% during the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company's stock worth $2,050,000 after acquiring an additional 9,170 shares during the last quarter. Ally Bridge Group NY LLC boosted its holdings in shares of Insmed by 16.9% during the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company's stock worth $11,011,000 after acquiring an additional 21,833 shares during the period. Finally, Vestal Point Capital LP grew its position in shares of Insmed by 113.3% in the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock valued at $116,800,000 after purchasing an additional 850,000 shares during the last quarter.

Remove Ads

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at approximately $27,079,091.58. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Martina M.D. Flammer sold 3,344 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the transaction, the insider now owns 102,766 shares in the company, valued at $6,773,307.06. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock worth $42,992,528 over the last quarter. Company insiders own 4.60% of the company's stock.

Insmed Trading Up 0.4 %

Shares of Insmed stock traded up $0.30 during midday trading on Friday, reaching $77.99. The company had a trading volume of 950,343 shares, compared to its average volume of 2,230,931. The stock has a fifty day moving average price of $78.18 and a 200 day moving average price of $74.00. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The firm has a market cap of $14.12 billion, a PE ratio of -13.95 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. On average, equities analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on INSM. Wells Fargo & Company lifted their price target on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. UBS Group lifted their target price on Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 target price on shares of Insmed in a research report on Wednesday, March 19th. Morgan Stanley raised their price objective on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Finally, HC Wainwright reissued a "buy" rating and issued a $90.00 target price on shares of Insmed in a report on Friday, February 21st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Insmed has a consensus rating of "Moderate Buy" and an average price target of $94.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.